Beijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Chin Med J (Engl). 2022 Nov 20;135(22):2677-2686. doi: 10.1097/CM9.0000000000002480.
It is controversial whether the apolipoprotein E epsilon 4 allele (APOE ε4) is a risk gene for human immunodeficiency virus (HIV)-related neurocognitive impairment. This meta-analysis aimed to summarize evidence of the associations between APOE ε4 and cognitive impairment in people living with HIV (PLWH).
Our study conducted a systematic literature search of PubMed, Web of Science, Embase, Google Scholar, and ProQuest for studies published before April 11, 2022 that evaluated associations between APOE ε4 and cognitive impairment in adult PLWH (aged ≥18 years). We calculated pooled odds ratios (ORs) of global cognitive impairment and 95% confidence intervals (CIs) and standardized mean differences (SMDs) for specific cognitive domains between APOE ε4 carriers and non-carriers. Subgroup meta-analyses were used to evaluate the result profiles across different categorical variables.
Twenty studies met the inclusion criteria, including 19 that evaluated global cognitive impairment. APOE ε4 was significantly associated with global cognitive impairment in PLWH (OR = 1.36, 95% CI = [1.05, 1.78], number of estimates [k] = 19, P = 0.02, random effects). Subgroup meta-analysis based percentage of females showed evident intergroup differences in global cognitive performance between ε4 carriers and non-carriers (P = 0.015). APOE ε4 carriers had lower cognitive test scores than non-carriers in all seven cognitive domains, including fluency (SMD = -0.51, 95% CI = [-0.76, -0.25], P < 0.001, k = 4, I2 = 0%), learning (SMD = -0.52, 95% CI = [-0.75, -0.28], P < 0.001, k = 5, I2 = 0%), executive function (SMD = -0.41, 95% CI = [-0.59, -0.23], P < 0.001, k = 8, I2 = 0%), memory (SMD = -0.41, 95% CI = [-0.61, -0.20], P < 0.001, k = 10, I2 = 36%), attention/working memory (SMD = -0.34, 95% CI = [-0.54, -0.14], P = 0.001, k = 6, I2 = 0%), speed of information processing (SMD = -0.34, 95% CI = [-0.53, -0.16], P < 0.001, k = 8, I2 = 0%), and motor function (SMD = -0.19, 95% CI = [-0.38, -0.01], P = 0.04, k = 7, I2 = 0%).
Our meta-analysis provides significant evidence that APOE ε4 is a risk genotype for HIV-associated cognitive impairment, especially in cognitive domains of fluency, learning, executive function, and memory. Moreover, the impairment is sex specific.
PROSPERO, CRD 42021257775.
载脂蛋白 E ɛ4 等位基因 (APOE ε4) 是否是人类免疫缺陷病毒 (HIV) 相关神经认知障碍的风险基因存在争议。本荟萃分析旨在总结 APOE ε4 与 HIV 感染者 (PLWH) 认知障碍之间关联的证据。
我们对发表于 2022 年 4 月 11 日之前的 PubMed、Web of Science、Embase、Google Scholar 和 ProQuest 等数据库进行了系统的文献检索,以评估 APOE ε4 与成年 PLWH(年龄≥18 岁)认知障碍之间的关联。我们计算了 APOE ε4 携带者与非携带者之间全球认知障碍和 95%置信区间 (CI) 以及特定认知域标准化均数差 (SMD) 的汇总比值比 (OR)。亚组荟萃分析用于评估不同分类变量下的结果分布。
共有 20 项研究符合纳入标准,其中 19 项评估了全球认知障碍。APOE ε4 与 PLWH 的全球认知障碍显著相关(OR=1.36,95%CI=[1.05, 1.78],估计数 k=19,P=0.02,随机效应)。基于女性比例的亚组荟萃分析显示,ε4 携带者与非携带者之间的整体认知表现存在明显的组间差异(P=0.015)。APOE ε4 携带者在所有七个认知域中的认知测试得分均低于非携带者,包括流畅性(SMD=-0.51,95%CI=[-0.76,-0.25],P<0.001,k=4,I2=0%)、学习(SMD=-0.52,95%CI=[-0.75,-0.28],P<0.001,k=5,I2=0%)、执行功能(SMD=-0.41,95%CI=[-0.59,-0.23],P<0.001,k=8,I2=0%)、记忆(SMD=-0.41,95%CI=[-0.61,-0.20],P<0.001,k=10,I2=36%)、注意力/工作记忆(SMD=-0.34,95%CI=[-0.54,-0.14],P=0.001,k=6,I2=0%)、信息处理速度(SMD=-0.34,95%CI=[-0.53,-0.16],P<0.001,k=8,I2=0%)和运动功能(SMD=-0.19,95%CI=[-0.38,-0.01],P=0.04,k=7,I2=0%)。
本荟萃分析提供了重要证据,表明 APOE ε4 是 HIV 相关认知障碍的风险基因型,特别是在流畅性、学习、执行功能和记忆等认知域。此外,这种损害具有性别特异性。
PROSPERO,CRD42021257775。